DEA and the Department of Justice have built a recognizable pattern for prosecuting telehealth clinicians who prescribe ADHD stimulants at volume: a platform that ties pay to the number of prescriptions written, encounters measured in minutes, and refills signed without anyone opening the chart. A 2026 DOJ sentencing tied one telehealth company's founder and its clinical president to exactly that pattern. For a clinician prescribing amphetamine-class stimulants or methylphenidate for ADHD, the question DEA and DOJ ask first is rarely whether the diagnosis was correct. It is whether the clinical record proves the evaluation happened.
How DEA and DOJ Build a Stimulant Prescribing Case
Federal investigators start with data, not a single complaint. DEA's prescription monitoring data and pharmacy dispensing records flag prescribers whose stimulant volume, patient panel size, or refill pattern sits far outside the norm for an in-person ADHD practice. Pharmacy chains that stop filling a platform's prescriptions and family complaints about a patient's condition add detail to the pattern. In the 2026 case, prosecutors pointed to prescribers who issued refills without reviewing records and patients who went years without seeing a clinician despite continuous authorizations, facts drawn from the Department of Justice's own announcement of the sentencing. None of that proof turns on the stimulant itself. It turns on what the record shows happened, or did not happen, before the prescription was written.
The prescription is rarely the evidence that decides a DEA or DOJ stimulant case. The clinical record behind it is.
The DEA Telemedicine Rules in Effect Right Now
A temporary DEA and HHS rule, extended four times since the COVID-19 public health emergency ended, currently lets a DEA-registered practitioner prescribe Schedule II through V controlled substances by telehealth without a prior in-person medical evaluation. That flexibility runs through December 31, 2026, and a separate rule creating permanent special registrations for telemedicine prescribing remained pending in federal review as this article was written. Prescribing stimulants under the current flexibility is lawful. It still has to meet every other requirement the Controlled Substances Act and state law impose: a legitimate medical purpose, a licensed prescriber, and a real-time audio-video encounter rather than a written questionnaire. The fuller framework is covered in Prescribing Controlled Substances via Telehealth: The Current Rules.
Civil and Criminal Exposure Beyond the Prescription
A stimulant prescribing investigation rarely stays contained to the prescription pad. If a platform pays prescribers or marketers based on patient volume or prescription counts, DOJ and HHS-OIG examine the arrangement under the Anti-Kickback Statute. If the platform billed insurers or federal health programs for visits that did not meet the clinical standard the biller certified, the exposure runs to the False Claims Act. Which document arrives first signals how serious the matter already is to the government. A civil investigative demand points to a civil fraud inquiry still testing the facts. A grand jury subpoena means prosecutors are already building a criminal case. Providers who respond to both the same way lose the chance to calibrate the response to what is actually in front of them.
The Records That Defend Legitimate Stimulant Care
The clinicians who come out of a DEA or DOJ review intact are the ones whose charts already answer the government's questions. That means a documented clinical evaluation specific to each patient, not a template; notes that show which recognized clinical criteria were applied during that specific visit; a medical necessity determination tied to that patient's own symptoms and history; and informed consent that reflects an actual conversation about the risks of a Schedule II stimulant. Prescribers who see a patient only for a rushed refill, with no updated evaluation, are the ones auditors and prosecutors flag first. What auditors pull first, and how to assemble that record before they ask, is covered in When Auditors Pull Telehealth Prescribing Records.
Why Early Legal Counsel Is Critical
It is critical that telehealth clinicians and platforms promptly retain experienced healthcare defense counsel upon receiving a DEA document request, a subpoena, or any other government inquiry touching on stimulant prescribing. Early legal intervention can protect the provider's rights, help shape appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience. The firm defends telehealth clinicians, platforms, and practice owners facing DEA inquiries and DOJ investigations into stimulant prescribing. If your telehealth practice is facing a DEA or DOJ inquiry into stimulant prescribing, contact us for a free, confidential consultation through our telehealth defense page.
